In recent years, artificial intelligence has been applied to many aspects such as medical image recognition, disease-assisted diagnosis, surgery, gene sequencing, and medical big data . In 2017, the State Council’s “New Generation Artificial Intelligence Development Plan†was introduced to the entire big health industry. The release of a significant positive signal, medical AI has become a hot vent. However, there are still certain problems in the current medical service system in China, and medical AI is also facing enormous challenges. In this situation, policies, technologies, and capital have become the main driving force for innovation and innovation in the medical industry. On October 28, 2018, the “Capital Assistance Medical Artificial Intelligence Industry Upgrade†forum hosted by Bank of China Group Investment Co., Ltd. was held in Chengdu. Mr. Gong Jianzhong, Executive Director of Bank of China Group Investment Co., Ltd., Song Anzhen, Partner of Softbank China, Zhang Jianbin, Partner of IDG Capital, Wu Yongxian, Associate Partner of McKinsey Global Director, Fan Li, Vice President of EDDA Technology, Sun Xiaorong, Chairman and General Manager of Landing Hi-Tech, Yang Cuijun, Chairman of Yu Technology, Vice President and Secretary of Board of Anhan Medical, Dan Dan, Chairman of the Board of Medical Sciences, Wang Peng, Founder and CEO of Xi's Heterogene, Song Jie, Director of the Imaging Department of Zhejiang People's Hospital, Gong Xiangyang, People of Sichuan Province Wang Dong, director of the hospital robot micro-invasive center, and other industry elites and medical experts participated in the forum, focusing on the development trend of artificial intelligence on auxiliary diagnosis, enabling medical and other sub-fields, business closed-loop, capital investment opportunities and other issues. Discussion. The organizer, Bank of China Group Investment Co., Ltd. is a wholly-owned subsidiary of Bank of China. It is a professional investment management company with various forms of investment activities in Hong Kong, Macao, the Mainland and overseas. The investment fields include medical, consumer, energy, transportation, finance and other industries. . Capital layout medical AI, what is the company? Artificial intelligence has received widespread attention since 2017, and 2017 is also known as the "first year of artificial intelligence." According to the data of the arterial network database, there were 27 financing incidents in the domestic medical artificial intelligence industry this year, with a total financing of more than 1.7 billion yuan. In 2018, there were more than 130 medical artificial intelligence enterprises in China, and the head enterprises entered the transformation and optimization of the business model in the new year. At the same time, they also fell into the problem of being able to identify the core of the clinical. After a round of enthusiasm, AI+ medical treatment gradually subsided. High-value and high-growth enterprises also allowed capital to enter a calm thinking period. Whether it can be better used for clinical application has become an important factor for investment. At this stage, how companies grasp opportunities and how to combine capital with industry has become the core focus of this forum. Mr. Gong Jianzhong, Executive Director of Bank of China Group Investment Co., Ltd. (hereinafter referred to as “BOC Investmentâ€), said that the core issues of “Capital Assistance in Smart Medical Industry Upgrade†said that for AI, data, algorithms and scenarios are when IB invests in AI companies. The core point of attention. Data quality is the basis for the development of medical AI. How to transform the basic algorithm into the application algorithm is the key to the development of AI enterprise, and intellectual property is the core competitiveness of the enterprise. The current pain point between the medical health industry and investment lies in the unclear production chain and the ambiguity of the capital boundary. For enterprises and capital, they should find their own positioning, linkage development, and let capital become the "accelerator" of enterprises and even the entire health industry. . BOC’s investment preference in the AI ​​medical field “from 1 to Nâ€, Mr. Gong Jianzhong said: “'1' refers to the fact that the company has transformed its intellectual property into a more mature product with commercial promotion conditions and Prospects; through the help of capital, not only can enterprises provide commercialized funds, but also can discuss and optimize the upgrades and upgrades of technical routes, product routes, business models, marketing networks, etc., so that the products of the invested companies or The service was successfully introduced to the market and reached the 'N' stage of widespread application." In addition, Mr. Gong Jianzhong also pointed out that investment institutions investing in the early stage, such as Morningside Ventures and Softbank China, provided early support and assistance to start-ups, including BOC, which focuses on different investment stages. For the joint efforts to help entrepreneurs further develop. At the venue, Mr. Song Anzhen, a partner of Softbank China, also deconstructed the industrial chain of AI and the investment logic of capital by taking the layout of Softbank in the medical field as an example. China's artificial intelligence market has maintained a high growth rate since 2017. According to Softbank China's forecast, the growth rate will be higher than 40% in the next few years. Following the PC Internet in 2000 and the mobile Internet in 2010, artificial intelligence is the next wave of disruptive technology, and it is a “land of competition†for venture capital. AI has penetrated into various industries in the medical field, and new capabilities and new business models have brought about an increase in efficiency and a reduction in costs. Mr. Song Anzhen said: "Softbank China has a long-term layout in the AI ​​field, but we believe that when investing, we must pay attention to caution, and we must have the choice to do projects. Artificial intelligence is not all successful, selectivity is very Important investment points." As one of the world's most well-known consulting organizations, Mr. Wu Yongxian, the global partner of McKinsey's global director, brings more in-depth statistics on the health care industry, and insight into the investment trends and opportunities of healthcare technology. According to McKinsey's analysis of investment data in the past two years, the investment in the healthcare industry has five main trends: First, China's medical industry is undergoing changes. In recent years, China's medical investment has been particularly active in terms of investment events, investment amounts, and types of companies; Second, product and technological innovation are increasingly becoming the subject of investment, such as investment in artificial intelligence and genetic diagnosis; Third, the volume of international M&A transactions has surged; Fourth, due to policy innovation and driving, China is increasingly leading the world in technology development and investment in medical platforms; Fifth, the extensive cooperation of the medical ecosystem has become a trend, including the exploration of business models with the technology industry, and investment cooperation with VC/PE. Exploring model innovation from the actual needs of medical care As the core driving force for the development of medical AI, innovative enterprises play a pivotal role in the industrial ecological chain. Technological innovation and model innovation are the development priorities of medical AI companies at this stage. With the popularization of the concept of “treatment without diseaseâ€, artificial intelligence plays an increasingly important role in the early stage of cancer screening. Landing High Tech is one of the first companies in China to apply medical AI to clinical tumor cell diagnosis and achieve commercialization results. Through decades of deep cultivation, Landing High Tech has continuously upgraded its own technology and services, and successfully realized the continuous expansion and deepening of the application of artificial intelligence in the field of screening. Ms. Sun Xiaorong, Chairman and General Manager of Landing Hi-Tech, believes that as a technology innovation enterprise, while gradually improving its own strength and creativity, it is also necessary to pay attention to how the clinical application is carried out and the feasibility of the commercialization plan. "The first thing that comes to mind as a business is not that you have to pay for the artificial intelligence diagnosis market, but how to get involved in the market." Ms. Fan Li, vice president of EDDA Technology, believes that the most important feature of medical artificial intelligence, especially in precision surgery, is to deal with people. "We want doctors to like it, and the products should be easy to use. The actual clinical effect is significant. We believe that the core of medical artificial intelligence is people-oriented, not human." Compared with the artificial intelligence enterprises in the early diagnosis category, EDDA Technology's IQQA enabling platform has passed many FDA approvals and China CFDA approval, and has been widely used in clinical practice. IQQA has more than 45,000 clinical cases of precision surgery, which effectively assists doctors in effective and accurate surgical planning. IQQA users include nine of the top ten Chinese hospitals and five of the top ten in the United States. The user hospitals independently publish more than 250 clinical papers. The "medical impossible triangle" problem needs to introduce new technology increments, and the emergence of new technology bodies will change the way of activities, industry composition and institutional arrangements. The arrival of new technologies will cause the expansion of prices and production networks in the economic system. Adjustment. In response to the pain points of the diagnosis and treatment of digestive diseases, Anhan Medical developed a capsule gastroscope robot to achieve a breakthrough of 1 to 0.01 meters. Based on the existing technology, in addition to examining the capsule robot of the digestive tract, Anhan has also developed a vibrating capsule robot that expands the product into the therapeutic field. An Han Medical Vice President and Secretary of the Board of Directors Ms. Yan Dandan said: "The capsules on the digestive tract terminal nerve massage can treat high-risk constipation problems, and also solve the high-risk population of the elderly, pregnant women are not suitable for eating chemicals and drug resistance. The pain point." Doctors need AI and are AIs that can be used for clinical applications. In the final round table, Mr. Gong Xiangyang, Director of the Department of Radiology of Zhejiang People's Hospital, and Mr. Wang Dong, Director of the Sichuan Mini-Invasion Center of Sichuan Provincial People's Hospital and Sichuan Provincial People's Hospital, talked about the doctor's demand for artificial intelligence technology from the perspective of doctors. Mr. Gong Xiangyang believes that it is very important that medical AI products fit into the clinic and can enter the workflow. "Medical care should be driven by demand, and problems can be found in clinical situations. AI is just one of them." Mr. Wang Dong said: “From pre-diagnosis screening to in-patient treatment, such as the surgical procedure of the surgeon, the examination of the physician, the rehabilitation and follow-up after treatment, we hope to achieve true AI in every aspect. Improve efficiency and precision. When talking about the application of AI in the field of diabetes, Mr. Yang Cuijun, chairman of the company, said that diabetes is not a serious illness, but it is very troublesome. AI can realize intelligent monitoring and intelligent treatment in the field of diabetes. After intelligent monitoring and intelligent treatment, it is actually artificial intelligence. The pain point of doing AI in the field of diabetes is that although the amount of data generated by diabetes is huge every day, there is a lot of redundant information. "The blood sugar is constantly fluctuating. The blood sugar is affected by emotions, environment and lifestyle. Therefore, diabetes In addition to training the model, AI also needs to have certain reasoning ability." “Traditional offline processes are cumbersome and inefficient. In the process of device circulation, offline transaction data is usually generated. It is almost a year and a half to use these data to improve the product in the simplest process.†Mr. Wang Peng, Chairman of Lianhe Medical, said that the application of artificial intelligence in the field of circulation has largely improved the efficiency of the industry. From the producer to the terminal, medical devices will go through many links. Through artificial intelligence personality matching or data mining, it is very helpful to help Chinese product manufacturers to describe the end user needs, what kind of users are in use, what are the price requirements, and what kind of product needs are improved. When the investor representative answered how to choose AI corporate investment, IDG Capital Partner Mr. Zhang Jianbin said that the “hard†products that truly meet the market demand and can lead the space and land in the future are favored by IDG Capital. The key to the upgrade of the artificial intelligence-enabled medical industry lies in the change of the supply side and the improvement of the performance, such as the Anhan Medical and EDDA technology. In addition, the company's products also need to solve the current application of artificial intelligence in the entire medical field, such as ethical barriers, legal barriers, medical barriers, and charging barriers. This forum has come to an end in deep opinions and discussions. We have reason to believe that this forum is only the beginning of the discussion on the development and investment of medical artificial intelligence industry. In the future, we also expect capital to help medical artificial intelligence, so that it can be realized. Industrial upgrading! Starch Empty Capsule,Starch Empty Capsule Shell,Starch Clear Pill Capsules Empty,Starch Hard Empty Capsule Ningbo Jiangnan Capsule Co., Ltd. , https://www.ningbocapsule.com